SCHEMBL6880918

SCHEMBL6880918

Cc1ccccc1Oc1nc(S(C)(=O)=O)ncc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HPGD P15428 1/20 0.47
PIN1 Q13526 1/20 0.41
ALDH1A1 P00352 4/20 0.40
TDP1 Q9NUW8 1/20 0.40
LDHA P00338 1/20 0.39
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.39
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
JAK3 P52333 1/20 0.37
NPSR1 Q6W5P4 2/20 0.37
TP53 P04637 2/20 0.37
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37
XBP1 P17861 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6880043 0.87 HTT (0.51) MEN1KMT2AHPGDPIN1ALDH1A1
SCHEMBL6872452 0.86 KMT2A (0.43) MEN1KMT2APIN1TDP1NPC1
SCHEMBL6871084 0.86 PIN1 (0.46) MEN1KMT2APIN1ALDH1A1TDP1
SCHEMBL6877899 0.85 MEN1 (0.60) MEN1KMT2APIN1ALDH1A1TDP1
SCHEMBL6883258 0.85 CYP1A2 (0.42) MEN1KMT2AHPGDPIN1TDP1
SCHEMBL7172328 0.82 MEN1 (0.42) MEN1KMT2AHPGDPIN1ALDH1A1
SCHEMBL6878851 0.82 MEN1 (0.49) MEN1KMT2AHPGDPIN1ALDH1A1
SCHEMBL6881040 0.80 MAPT (0.49) MEN1KMT2ATDP1NPSR1MAPT
SCHEMBL5126068 0.79 KMT2A (0.71) MEN1KMT2AHPGDALDH1A1TDP1
SCHEMBL6880096 0.79 RXFP1 (0.49) MEN1KMT2APIN1ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives HOFFMANN-LA ROCHE INC. 2002-07-25 US claimed
US-6787539-B2 HAS ACTIVITY AS AN ANTAGONIST TO NEUROKININ 1 RECEPTORS; FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA (BPH) HOFFMANN-LA ROCHE INC. 2004-09-07 US disclosed
EP-1339698-A2 PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-03 EP disclosed
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives HOFFMANN-LA ROCHE INC. 2002-07-25 US disclosed
WO-2002042280-A2 PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives TACR1, TACR2, P2RY2 MEN1 3228/4885KMT2A 1436/4885HPGD 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.